Advertisement

Combination chemotherapy in the treatment of inoperable non-small cell lung cancer

  • R. M. Rutherford
  • T. Azher
  • J. J. Gilmartin
Original Paper

Abstract

Background

Chemotherapy is an established intervention in inoperable non-small cell lung cancer (NSCLC), yet few Irish patients receive this treatment.

Aim

To determine survival, toxicity and radiological response following chemotherapy for NSCLC at our institution.

Methods

Retrospective audit of all patients receiving chemotherapy for histologically proven, inoperable NSCLC from January 1997 to December 2000.

Results

There were 80 treatment episodes in 77 patients, mean age 62 years. Forty-eight (60%) patients had locally advanced and 32 (40%) metastatic disease. Mitomycin, Ifosfamide, Carboplatin (MIC) and Paclitaxel/Carboplatin (PC) were the most commonly administered regimens. Median survival for locally advanced and metastatic disease was 13.9 months and 7.1 months respectively. Severe neutropenia and thrombocytopenia were each witnessed after less than 9% of cycles. Eleven (16.7%) patients had radiological response including 4 (6.1%) complete responses.

Conclusion

Survival for inoperable NSCLC treated with chemotherapy was encouraging and achieved at low toxicity.

Keywords

Paclitaxel Carboplatin Clin Oncol Malignant Pleural Effusion Best Supportive Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Cancer Registry Ireland. Cancer in Ireland, 1997. Incidence and Mortality.Lung Cancer 63–70.Google Scholar
  2. 2.
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individuals patients from 52 randomised clinical trials.BMJ 1995; 311: 899–909.Google Scholar
  3. 3.
    Cullen MH. The MIC regimen in non-small cell lung cancer.Lung Cancer 1993; 9 (Suppl 2): 81–9.CrossRefGoogle Scholar
  4. 4.
    Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced nonsmall cell lung cancer.Br J Cancer 1989; 60: 764–6.PubMedGoogle Scholar
  5. 5.
    Billingham LJ, Cullen MH, Woods AD, Chetiyawardana RC. Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer. Results of a randomised trial evaluating palliation and quality of life (abstract).Lung Cancer 1997; 18 (Suppl 1):9.CrossRefGoogle Scholar
  6. 6.
    Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer — a randomised trial with quality of life as the primary outcome.Br J Cancer 2000; 83: 447–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Roszkowski K, Pluzanska A, Krzakowski M et al. A multi-center, randomised, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC).Lung Cancer 2000; 27: 145–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.Clin Cancer Res 1998; 4: 1087–100.PubMedGoogle Scholar
  9. 9.
    Manegold C, Bergman B, Chemaissani A et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer.Ann Oncol 1997; 8: 525–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced nonsmall cell lung cancer: a Southwest Oncology Group Study.J Clin Oncol 1998; 16: 2459–65.PubMedGoogle Scholar
  11. 11.
    Kindler HL, Kris MG, Smith IE et al. Phase II trial of topetecan administered as a 21 day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer.Am J Clin Oncol 1998; 21: 438–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small cell lung cancer: seven year follow up of cancer and leukaemia group B (CALGB) 8433 trial.J Natl Cancer Inst 1996; 88: 1210–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide and cisplatin (MIC) in unresectable non-small cell lung cancer: Effects on survival and quality of life.J Clin Oncol 1999; 17: 3188–94.PubMedGoogle Scholar
  14. 14.
    Rosell R, Gomez-Codina J, Camps C et al. A randomised trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer.N Engl J Med 1994; 330: 153–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Crino L, Clerici M, Figoli F et al. Chemotherapy of advanced non-small cell lung cancer: A comparison of three active regimens — a randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).Ann Oncol 1995; 6: 347–53.PubMedGoogle Scholar
  16. 16.
    Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in Stage IV non-small cell lung cancer. A study of the Eastern Cooperative Oncology Group.J Clin Oncol 1989; 7: 1602–13.PubMedGoogle Scholar
  17. 17.
    Green MR, Kreisman H, Lickart S et al. Carboplatin in non-small cell lung cancers: the Cancer and Leukaemia Group B experience, in Bunn PA Jr, Canetta R, Ozol R et al (eds): Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia, PA, Saunders, 1990. pp301–16.Google Scholar
  18. 18.
    Ranson M, Davidson N, Nicholson M et al. Randomised trial of paclitaxel versus supportive care for patients with advanced non-small cell lung cancer.J Natl Cancer Inst 2000; 92: 1074–80.CrossRefPubMedGoogle Scholar
  19. 19.
    Bonomi P, KyungMann K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial.J Clin Oncol 2000; 18: 623–31.PubMedGoogle Scholar
  20. 20.
    Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis.J Clin Oncol 1995; 13: 1860–70.PubMedGoogle Scholar
  21. 21.
    Johnson DH, Paul DM, Hande KR et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial.J Clin Oncol 1996; 14: 2054–60.PubMedGoogle Scholar
  22. 22.
    Giaccone G, Splinter TA, Debruyne C et al. Randomised study of paclitaxelcisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer.J Clin Oncol 1998; 16: 2133–41.PubMedGoogle Scholar
  23. 23.
    Raymond E, Hanauske A, Faivre S et al. Effects of prolonged versus shortterm exposure paclitaxel (Taxol) on human tumour colony forming units.Anticancer Drugs 1997; 8: 379–85.CrossRefPubMedGoogle Scholar
  24. 24.
    Muggia FM, Vafai D, Natale R et al. Paclitaxel three hour infusion given alone and combined with carboplatin: preliminary results of a dose escalation trials.Semin Oncol 1995; 22 (4 Suppl 9); 63–6.PubMedGoogle Scholar
  25. 25.
    Giaccone G, Huizing M, Postmus PE et al. Dose finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.Semin Oncol 1995; 22 (4 Suppl 9): 78–82.PubMedGoogle Scholar

Copyright information

© Springer 2002

Authors and Affiliations

  1. 1.Department of Respiratory MedicineMerlin Park HospitalGalwayIreland

Personalised recommendations